Market
How many data readouts will Moderna have from its prioritized programs in 2025?
2
Resolution / Starting Odds
0-2 • 25%
3-4 • 25%
5-6 • 25%
More than 6 • 25%
Moderna's official announcements or scientific publications
Story
Moderna Cuts 2025 Revenue Forecast to $1.5B-$2.5B, Plans $1B Cost Reduction Amid 20% Stock Drop
Jan 13, 2025, 12:28 PM
Moderna Inc. has revised its 2025 revenue forecast downwards to a range of $1.5 billion to $2.5 billion, a significant reduction from its previous projection of $2.5 billion to $3.5 billion. This adjustment comes in response to slower-than-expected demand for its Covid-19 and RSV vaccines. The company also reported 2024 product sales of between $3.0 billion and $3.1 billion, with an ending cash balance of approximately $9.5 billion. Moderna anticipates ending 2025 with a cash balance of about $6.0 billion. In an effort to manage costs, the company plans to reduce 2025 cash cost expenses by $1 billion, with an additional $0.5 billion in cost reductions targeted for 2026. Moderna is also focusing on its pipeline, anticipating milestones across 10 prioritized programs, including up to three potential approvals and six data readouts in 2025. The company's stock experienced a sharp decline, falling 20% in pre-market trading following the announcement.
View original story
Similar markets
More than 3 additional subtypes • 25%
3 additional subtypes • 25%
1 additional subtype • 25%
2 additional subtypes • 25%
3-4 subtypes • 25%
5 subtypes • 25%
1-2 subtypes • 25%
More than 5 subtypes • 25%
Ongoing • 25%
Unsuccessful • 25%
Successful without FDA approval • 25%
Successful with FDA approval • 25%
Positive safety and immunogenicity results • 25%
Study inconclusive • 25%
Negative immunogenicity results • 25%
Negative safety results • 25%
Successful with FDA approval recommendation • 25%
Unsuccessful • 25%
Successful without FDA approval recommendation • 25%
Delayed • 25%
Top 10 • 25%
Below Top 20 • 25%
Top 5 • 25%
Top 20 • 25%
Other • 25%
Achieves $1 billion reduction • 25%
Exceeds $1 billion reduction • 25%
Fails to achieve $1 billion reduction • 25%
10 to 50 million • 25%
50 to 100 million • 25%
More than 100 million • 25%
Less than 10 million • 25%
Less than 10 million doses • 25%
More than 100 million doses • 25%
50 to 100 million doses • 25%
10 to 50 million doses • 25%